Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 3/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.45 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | FABP4 | P15090 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5011993 | 0.91 | ADORA1 (0.52) | MAPTMEN1LMNAGAAMAPK1 | |
| SCHEMBL5008344 | 0.86 | GFER (0.52) | MAPTLMNAGAAKMT2AL3MBTL1 | |
| SCHEMBL5007754 | 0.86 | ADORA1 (0.52) | MAPTMEN1LMNAGAAMAPK1 | |
| SCHEMBL3973559 | 0.85 | MAP4K2 (0.50) | MAPTLMNAMAPK1KDM4ETP53 | |
| SCHEMBL27637105 | 0.85 | MAPT (0.46) | MAPTMEN1LMNAGAAMAPK1 | |
| SCHEMBL5011998 | 0.85 | MAPT (0.59) | MAPTMEN1LMNAGAAMAPK1 | |
| SCHEMBL5008323 | 0.84 | ADORA1 (0.54) | MAPTTP53POLBADORA1GRM5 | |
| SCHEMBL5008775 | 0.83 | ADORA1 (0.55) | MAPTMEN1LMNAGAAMAPK1 | |
| SCHEMBL5012026 | 0.83 | MAPT (0.44) | MAPTMEN1LMNAGAAMAPK1 | |
| SCHEMBL5008529 | 0.82 | MAPK14 (0.59) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064734-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-03-13 | — | — | US | disclosed |
| US-7265144-B2 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064734-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | IAPP, GLP1R, GPR119 | MAPT 2420/4885MEN1 4148/4885LMNA 3247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.